203 related articles for article (PubMed ID: 17288876)
1. Pazopanib: a novel multitargeted tyrosine kinase inhibitor.
Sonpavde G; Hutson TE
Curr Oncol Rep; 2007 Mar; 9(2):115-9. PubMed ID: 17288876
[TBL] [Abstract][Full Text] [Related]
2. Pazopanib, a potent orally administered small-molecule multitargeted tyrosine kinase inhibitor for renal cell carcinoma.
Sonpavde G; Hutson TE; Sternberg CN
Expert Opin Investig Drugs; 2008 Feb; 17(2):253-61. PubMed ID: 18230058
[TBL] [Abstract][Full Text] [Related]
3. Pazopanib for the treatment of renal cell carcinoma and other malignancies.
Sonpavde G; Hutson TE; Sternberg CN
Drugs Today (Barc); 2009 Sep; 45(9):651-61. PubMed ID: 19956806
[TBL] [Abstract][Full Text] [Related]
4. Pazopanib for the treatment of metastatic renal cell carcinoma.
Pick AM; Nystrom KK
Clin Ther; 2012 Mar; 34(3):511-20. PubMed ID: 22341567
[TBL] [Abstract][Full Text] [Related]
5. Pazopanib: therapeutic developments.
Limvorasak S; Posadas EM
Expert Opin Pharmacother; 2009 Dec; 10(18):3091-102. PubMed ID: 19954277
[TBL] [Abstract][Full Text] [Related]
6. Pazopanib, a VEGF receptor tyrosine kinase inhibitor for cancer therapy.
Sloan B; Scheinfeld NS
Curr Opin Investig Drugs; 2008 Dec; 9(12):1324-35. PubMed ID: 19037839
[TBL] [Abstract][Full Text] [Related]
7. Pazopanib for the treatment of breast cancer.
Amiri-Kordestani L; Tan AR; Swain SM
Expert Opin Investig Drugs; 2012 Feb; 21(2):217-25. PubMed ID: 22233389
[TBL] [Abstract][Full Text] [Related]
8. Pazopanib for the treatment of renal cancer.
Al-Marrawi MY; Rini B
Expert Opin Pharmacother; 2011 May; 12(7):1171-89. PubMed ID: 21470066
[TBL] [Abstract][Full Text] [Related]
9. Pazopanib in renal cell carcinoma.
Ward JE; Stadler WM
Clin Cancer Res; 2010 Dec; 16(24):5923-7. PubMed ID: 21059813
[TBL] [Abstract][Full Text] [Related]
10. Pazopanib: a promising new agent in the treatment of soft tissue sarcomas.
Kasper B; Hohenberger P
Future Oncol; 2011 Dec; 7(12):1373-83. PubMed ID: 22112314
[TBL] [Abstract][Full Text] [Related]
11. Pazopanib: a new multiple tyrosine kinase inhibitor in the therapy of metastatic renal cell carcinoma and other solid tumors.
Melichar B; Studentová H; Zezulová M
J BUON; 2011; 16(2):203-9. PubMed ID: 21766486
[TBL] [Abstract][Full Text] [Related]
12. Pazopanib: an antiangiogenic drug in perspective.
Castaneda CA; Gomez HL
Future Oncol; 2009 Nov; 5(9):1335-48. PubMed ID: 19903063
[TBL] [Abstract][Full Text] [Related]
13. Initial testing of the multitargeted kinase inhibitor pazopanib by the Pediatric Preclinical Testing Program.
Keir ST; Morton CL; Wu J; Kurmasheva RT; Houghton PJ; Smith MA
Pediatr Blood Cancer; 2012 Sep; 59(3):586-8. PubMed ID: 22190407
[TBL] [Abstract][Full Text] [Related]
14. [Pazopanib (Votrient) in the management of renal cell cancer and soft tissue sarcomas].
Gennigens C; Jerusalem G
Rev Med Liege; 2012; 67(7-8):437-42. PubMed ID: 22984765
[TBL] [Abstract][Full Text] [Related]
15. Pazopanib in ovarian cancer.
McLachlan J; Banerjee S
Expert Rev Anticancer Ther; 2015; 15(9):995-1005. PubMed ID: 26296187
[TBL] [Abstract][Full Text] [Related]
16. Pazopanib: an orally administered multi-targeted tyrosine kinase inhibitor for locally advanced or metastatic renal cell carcinoma.
Koc G; Wang X; Luo Y
Can J Urol; 2011 Dec; 18(6):5991-7. PubMed ID: 22166325
[TBL] [Abstract][Full Text] [Related]
17. Pazopanib for Non-small Cell Lung Cancer: The First Case Report in Korea.
Jo J; Kim JH; Kim JY; Hyun C; Rhee J; Kwon J; Han S; Kim W
Cancer Res Treat; 2016 Jan; 48(1):393-7. PubMed ID: 25715772
[TBL] [Abstract][Full Text] [Related]
18. Pazopanib: an oral multitargeted tyrosine kinase inhibitor for use in renal cell carcinoma.
LaPlant KD; Louzon PD
Ann Pharmacother; 2010 Jun; 44(6):1054-60. PubMed ID: 20407031
[TBL] [Abstract][Full Text] [Related]
19. Tyrosine kinases as targets in cancer therapy - successes and failures.
Traxler P
Expert Opin Ther Targets; 2003 Apr; 7(2):215-34. PubMed ID: 12667099
[TBL] [Abstract][Full Text] [Related]
20. Pazopanib: Clinical development of a potent anti-angiogenic drug.
Schutz FA; Choueiri TK; Sternberg CN
Crit Rev Oncol Hematol; 2011 Mar; 77(3):163-71. PubMed ID: 20456972
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]